Atossa Therapeutics (FRA:YAG2) ROE % Adjusted to Book Value : -14.92% (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Atossa Therapeutics ROE % Adjusted to Book Value?

Atossa Therapeutics's ROE % for the quarter that ended in Sep. 2024 was -37.00%. Atossa Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was 2.48. Atossa Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -14.92%.

Atossa Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Atossa Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics ROE % Adjusted to Book Value Chart

Atossa Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-140.26

-57.56

-17.40

-39.62

-20.38

Atossa Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-25.75	-23.32	-9.66	-16.75	-14.92

Competitive Comparison of Atossa Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Atossa Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atossa Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's ROE % Adjusted to Book Value falls into.

Atossa Therapeutics ROE % Adjusted to Book Value Calculation

Atossa Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-28.33%	/	1.39
	=	-20.38%

Atossa Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-37.00%	/	2.48
	=	-14.92%

Atossa Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (FRA:YAG2) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

ATOS:USA ATOS:Mexico

Address

107 Spring Street, Seattle, WA, USA, 98104

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics Headlines

No Headlines